Clinical trials: Cardiovascular (CV) Risk
Breast Cancer Survivorship, Weight Management
Weight Management After Cancer for Survivors in Rural Communities
This study is testing a new program called WeCan-Rural, designed to help breast cancer survivors manage symptoms and build healthy habits like eating well, staying active, and managing their weight.
- Conditions
- Breast Cancer Survivorship, Weight Management, Cardiovascular (CV) Risk, Breast Cancer
- Trial name
- WeCan-Rural (NCT07426952)
- Testing
- WeCan-Rural Program
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Duke University
Type 2 Diabetes, Overweight
Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk
Investigators are building an empirical evidence base for real-world data through large-scale emulation of randomized controlled trials.
- Conditions
- Type 2 Diabetes, Overweight, Cardiovascular (CV) Risk
- Trial name
- TIRZSEMA-CVOT (NCT07096063)
- Testing
- Tirzepatide, Dulaglutide, Semaglutide
- Where
- United States
- Volunteers
- 887,132 people
- Sponsor
- Brigham and Women's Hospital
Coronary Disease, Cardiovascular Diseases
Examining How Heart Disease Risk Factors Affect Healthy Aging (The Chicago Healthy Aging Study [CHAS])
Heart disease is the leading cause of death in the United States and is responsible for 30% of all deaths in the United States. This study will examine how risk factors for heart disease in young and middle aged people affect…
- Trial name
- CHAS (NCT00626379)
- Where
- United States
- Volunteers
- 1,395 people
- Sponsor
- Northwestern University
Cardiovascular (CV) Risk
Cardiometabolic Effects of Low-Fat and Full-Fat Dairy
The purpose of this study is to find out if full-fat dairy and low-fat dairy have similar effects on risk factors for heart disease and diabetes.
- Trial name
- NCT07605442
- Testing
- Full-fat dairy, Low-fat dairy
- Volunteers
- 178 people, healthy volunteers welcome
- Sponsor
- Penn State University
Coronary Disease, Diabetes Mellitus
A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To demonstrate if torcetrapib/atorvastatin can reduce the risk for major cardiovascular disease events, when compared to atorvastatin alone, in…
- Trial name
- ILLUMINATE (NCT00134264)
- Testing
- torcetrapib/atorvastatin, atorvastatin
- Where
- 221 sites in United States, Australia and 5 more
- Volunteers
- 15,067 people
- Sponsor
- Pfizer
Cardiovascular Risk, Prostate Cancer
The Effect of Multidisciplinary Care Approach on CV Risk Modification in CaP Patients Receiving ADT
Prostate cancer is characterised by its slow progression nature, and even for metastatic disease, the 5-year survival is up to 30%.
- Trial name
- NCT06163924
- Where
- Hong Kong
- Volunteers
- 130 people
- Sponsor
- Chinese University of Hong Kong
Cardiovascular Health Risk Communication, Cardiovascular (CV) Risk
Breast Artery Calcification (BAC) and Female Cardiovascular Disease
The investigators are recruiting women with and without Breast Artery Calcification (BAC) on their mammograms. Each participant in the study will undergo bloodwork at a Northwell Health lab, a cardiac CT scan, and fill out some…
- Conditions
- Cardiovascular Health Risk Communication, Cardiovascular (CV) Risk, Cardiovascular Disease Prevention
- Trial name
- NCT07809932
- Testing
- Cardiac CT Scan, Bloodwork
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Northwell Health
HIV, Menopause
The Synergistic Effects of Menopause and HIV on Cardiovascular Disease Risk in Women
Menopause is associated with the acceleration of many comorbidities, including cardiovascular disease. Whether HIV and menopause together increase cardiovascular disease risk is a key knowledge gap.
- Conditions
- HIV, Menopause, Cardiovascular (CV) Risk, Carotid Arteriosclerosis
- Trial name
- NCT07284082
- Testing
- Whole body MRI
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of California, San Francisco
Stable Coronary Disease
The Impact of Pcsk-9 Inhibition on PET CFR in Patients at High CV Risk
The study protocol is a single-arm, open label pilot study designed to evaluate the impact of PCSK-9 inhibition on coronary blood flow in patients with stable coronary artery disease.
- Trial name
- EMPOWER (NCT05152888)
- Testing
- Evolocumab
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Brigham and Women's Hospital
Major Coronary Event, Cerebrovascular Accident
CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events
A study to assess the efficacy of once daily atorvastatin 10 mg versus placebo on cardiovascular endpoints in patients with non-insulin-dependent diabetes mellitus (NIDDM) who have a history of either hypertension, retinopathy…
- Conditions
- Major Coronary Event, Cerebrovascular Accident, Coronary Artery Bypass Graft, Angina, Unstable
- Trial name
- CARDS (NCT00327418)
- Testing
- Atorvastatin
- Where
- 135 sites in United Kingdom
- Volunteers
- 2,800 people
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus, CV Risk
Cardiovascular (CV) Risk Evaluation In Type 2 Diabetes Subjects
The primary objective of this study is to assess the total CV risk in patients with type 2 diabetes and also to assess the impact of rosiglitazone in the total CV risk and the parameters of metabolic syndrome.
- Trial name
- NCT00648284
- Volunteers
- 1,100 people
- Sponsor
- GlaxoSmithKline
Atherosclerosis, Cardiovascular Disease
Homocysteine Lowering and Atherosclerosis Reduction Trial (HART)
Study Objective: 1. To evaluate whether combined therapy with folic acid 2.5 mg/day, vitamin B6 50 mg/day and vitamin B12 1000 micrograms/day vs placebo reduces the rate of atherosclerosis progression, as evaluated by…
- Trial name
- NCT00217178
- Testing
- Vitamins: Folic acid, B6, B12
- Where
- Canada
- Volunteers
- 900 people
- Sponsor
- Hamilton Health Sciences Corporation
Hypercholesterolaemia
Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Primary Objective: To collect real-use (usability) data assessing the robustness and user interaction of the new alirocumab auto-injector device (which is referred to as SYDNEY), in unsupervised settings.
- Trial name
- NCT03415178
- Testing
- Alirocumab SAR236553, Current auto-injector device (AI), New auto-injector device (SYDNEY)
- Where
- 13 sites in United States
- Volunteers
- 69 people
- Sponsor
- Sanofi
Prostate Cancer (Diagnosis), Prostate Cancer Stage IV
High Cardiovascular Risk Intervention With Cardio-Oncology Consultation for Prostate Cancer Following Androgen Receptor Pathway Inhibitor (ARPI) Therapy (Heart-Safe)
In patients with prostate cancer (PC), cardiovascular disease (CVD) causes significant morbidity and is the second leading cause of death.
- Conditions
- Prostate Cancer (Diagnosis), Prostate Cancer Stage IV, CV Risk
- Trial name
- NCT07223385
- Testing
- Cardio-Oncology Referral, Notification to PCP/General Cardiologist
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Cedars-Sinai Medical Center
Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD)
A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease
This multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the potential of dalcetrapib to reduce cardiovascular morbidity and mortality in patients with stable coronary heart disease…
- Trial name
- NCT01516541
- Testing
- Background care, dalcetrapib
- Where
- 241 sites in United States, Australia and 11 more
- Volunteers
- 2,220 people
- Sponsor
- Hoffmann-La Roche
Type 2 Diabetes, Major Adverse Cardiac Events
Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials.
- Conditions
- Type 2 Diabetes, Major Adverse Cardiac Events, Cardiovascular (CV) Risk
- Trial name
- DUP-SURPASS (NCT07088718)
- Testing
- Tirzepatide, Dulaglutide
- Where
- United States
- Volunteers
- 44,671 people
- Sponsor
- Brigham and Women's Hospital
Cardiovascular (CV) Risk, Behavioral Changes
Growing Healthy Hearts
This proposal includes a prospective, parallel group, two-arm RCT with 264 adult-child dyads (adult age 18+, child ages 5-17 years) to examine the effectiveness of the Growing Healthy Hearts (GHH) intervention versus a wait list…
- Conditions
- Cardiovascular (CV) Risk, Behavioral Changes, Gardening, Cooking
- Trial name
- GHH (NCT07684027)
- Testing
- GHH Intervention
- Where
- United States
- Volunteers
- 264 people
- Sponsor
- Milton S. Hershey Medical Center
Breast Cancer
Coronary Artery Calcium and Cardiovascular Risk Factors Analysis After RT or Breast Cancer
This is a no-profit, national, monocenter, retrospective, and prospective low-intervention study. It is a low-intervention study in terms of diagnostic additional procedure (CT scan).
- Trial name
- RadioTherapy (NCT05775822)
- Testing
- CT scan and blood sample collection
- Where
- Italy
- Volunteers
- 92 people
- Sponsor
- Centro Cardiologico Monzino
Cardiovascular (CV) Risk, Exercise
The Role of Mobile Apps in Promoting Cardiovascular Health and Motivation to Exercise During Pregnancy
The goal of this study is to determine the effectiveness of a mobile exercise app in improving cardiovascular health and motivation to exercise in pregnant women who are healthy, in their 2nd trimester, between 18-45 years age…
- Trial name
- NCT07166822
- Testing
- Experimental group using BumptUp mobile exercise app
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Old Dominion University
Hypertension
Impact of Ramadan on Achieving Joint National Committee (JNC) 7 Treatment Goals in CV Risk Patients
This is an out-patient based prospective, multi-centre, observational post-marketing surveillance study amongst internists and cardiologists.
- Trial name
- NCT01853839
- Where
- 132 sites in Algeria, Egypt and 3 more
- Volunteers
- 1,674 people
- Sponsor
- Boehringer Ingelheim